{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:27:00Z","timestamp":1767889620331,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.carrev.2018.12.019","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T03:24:40Z","timestamp":1545881080000},"page":"1001-1006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy"],"prefix":"10.1016","volume":"20","author":[{"given":"Rahul","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Kinderyt\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajaypaul","family":"Sukhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Bliden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2018.12.019_bb0005","author":"CDC"},{"key":"10.1016\/j.carrev.2018.12.019_bb0010","author":"Organization WH"},{"issue":"Suppl. 2","key":"10.1016\/j.carrev.2018.12.019_bb0015","article-title":"Abstract 16886: LDL4 \u2014 a novel predictor of coronary artery disease severity","volume":"130","author":"Bliden","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.12.019_bb0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5551\/jat.38844","article-title":"Association of high-density lipoprotein subclasses with carotid intima-media thickness: shimane CoHRE study","volume":"25","author":"Notsu","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"10.1016\/j.carrev.2018.12.019_bb0025","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/MAJ.0000000000000231","article-title":"High-density lipoprotein functionality in coronary artery disease","volume":"347","author":"Kosmas","year":"2014","journal-title":"Am J Med Sci"},{"issue":"14","key":"10.1016\/j.carrev.2018.12.019_bb0030","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.113.002670","article-title":"Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis","volume":"128","author":"Boekholdt","year":"2013","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.carrev.2018.12.019_bb0035","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jacc.2010.01.008","article-title":"High-density lipoprotein and coronary heart disease: current and future therapies","volume":"55","author":"Natarajan","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.12.019_bb0040","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.atherosclerosis.2016.06.019","article-title":"Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial","volume":"251","author":"Albers","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.carrev.2018.12.019_bb0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurheartj\/ehu264","article-title":"HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative","volume":"36","author":"Martin","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.carrev.2018.12.019_bb0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.tem.2014.05.005","article-title":"High-density lipoprotein subfractions: current views and clinical practice applications","volume":"25","author":"Martin","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.carrev.2018.12.019_bb0055","first-page":"79","article-title":"Application of the new cholesterol guidelines","volume":"371","author":"Navar-Boggan","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.carrev.2018.12.019_bb0060","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1161\/01.CIR.0000033635.42612.88","article-title":"Statins as potent Antiinflammatory drugs","volume":"106","author":"Lefer","year":"2002","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.carrev.2018.12.019_bb0065","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.carrev.2018.12.019_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MOL.0b013e3283453e41","article-title":"Mechanisms for the anti-inflammatory effects of statins","volume":"22","author":"Bu","year":"2011","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"10.1016\/j.carrev.2018.12.019_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10557-008-6113-z","article-title":"Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit","volume":"22","author":"McTaggart","year":"2008","journal-title":"Cardiovascular Drugs and Therapy\/Sponsored by the International Society of Cardiovascular Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.carrev.2018.12.019_bb0080","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","article-title":"Antiinflammatory properties of HDL","volume":"95","author":"Barter","year":"2004","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.carrev.2018.12.019_bb0085","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2174\/138161207780487520","article-title":"Apolipoprotein A-I\/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach","volume":"13","author":"Shah","year":"2007","journal-title":"Curr Pharm Des"},{"issue":"25 Pt B","key":"10.1016\/j.carrev.2018.12.019_bb0090","first-page":"2889","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.carrev.2018.12.019_bb0095","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/01.ATV.10.4.520","article-title":"Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia","volume":"10","author":"Austin","year":"1990","journal-title":"Arteriosclerosis"},{"issue":"16","key":"10.1016\/j.carrev.2018.12.019_bb0100","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"issue":"37","key":"10.1016\/j.carrev.2018.12.019_bb0105","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.2174\/138161211798764816","article-title":"Vulnerable plaque and inflammation: potential clinical strategies","volume":"17","author":"Drakopoulou","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"Suppl. 2","key":"10.1016\/j.carrev.2018.12.019_bb0110","article-title":"Abstract 16886: LDL4 \u2014 a novel predictor of coronary artery disease severity","volume":"130","author":"Bliden","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.carrev.2018.12.019_bb0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/MOL.0b013e328338472d","article-title":"High-density lipoprotein heterogeneity and function in reverse cholesterol transport","volume":"21","author":"Rothblat","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.carrev.2018.12.019_bb0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbacli.2015.01.005","article-title":"High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk","volume":"3","author":"Hafiane","year":"2015","journal-title":"BBA clinical"},{"issue":"1","key":"10.1016\/j.carrev.2018.12.019_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/2047487314543890","article-title":"Association of high-density lipoprotein subclasses and incident coronary heart disease: the Jackson Heart and Framingham Offspring Cohort Studies","volume":"23","author":"Joshi","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"10.1016\/j.carrev.2018.12.019_bb0130","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.amjcard.2016.08.067","article-title":"Impact of lipoprotein(a) on long-term outcomes in patients with diabetes mellitus who underwent percutaneous coronary intervention","volume":"118","author":"Konishi","year":"2016","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.carrev.2018.12.019_bb0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2014.10.015","article-title":"Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention","volume":"115","author":"Konishi","year":"2015","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.carrev.2018.12.019_bb0140","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1155\/2013\/472845","article-title":"Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement","volume":"35","author":"Cai","year":"2013","journal-title":"Dis Markers"},{"issue":"12","key":"10.1016\/j.carrev.2018.12.019_bb0145","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.carrev.2018.12.019_bb0150","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","article-title":"Coronary plaque disruption","volume":"92","author":"Falk","year":"1995","journal-title":"Circulation"},{"issue":"Suppl","key":"10.1016\/j.carrev.2018.12.019_bb0155","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1194\/jlr.R800034-JLR200","article-title":"The metabolism and anti-atherogenic properties of HDL","volume":"50","author":"Rye","year":"2009","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.carrev.2018.12.019_bb0160","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit Arterial Wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918306225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918306225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:15:23Z","timestamp":1761560123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838918306225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1553838918306225"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2018.12.019","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2018.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}